SIGA Technologies, Inc. Overview
Pro stress-test →SIGA Technologies is a commercial-stage pharmaceutical company specializing in health security with a focus on treating serious infectious diseases. Its flagship product TPOXX (tecovirimat) is an FDA-approved antiviral for smallpox treatment and is authorized internationally for smallpox, monkeypox, cowpox, and vaccinia complications, with significant revenue derived from U.S. government contracts.
Strategic Profile
Pro stress-test →SIGA maintains a strong strategic position through four key pillars: continued partnership with the U.S. government (primary revenue source), advancing regulatory approvals for new TPOXX indications and formulations, expanding international market access, and developing complementary therapeutic areas. The company has strong financial flexibility with $182 million in cash, no debt, and is pursuing post-exposure prophylaxis (PEP) and pediatric formulations to drive future growth.
Competitive Landscape
Pro stress-test →SIGA operates in a specialized market focused on biodefense and orthopoxvirus treatments. The company faces limited direct competition for smallpox treatments, though monkeypox/mpox treatment space has become more competitive. Key competitive advantages include TPOXX's first-mover status, FDA/international approvals across multiple indications, and established U.S. government relationship. Potential future competitors include companies developing alternative antivirals or monoclonal antibodies for orthopoxviruses.
Industry Context
SIGA Technologies, Inc. operates in Pharmaceutical/Biotech - Health Security & Infectious Diseases.
Key facts
Founded: 1995 · Headquarters: New York, US · Employees: 46 · Revenue: N/A · Market cap: $483M